Smart chemo: tailoring breast cancer treatment to each Patient's genes
NCT ID NCT07239271
First seen Nov 20, 2025 · Last updated May 25, 2026 · Updated 23 times
Summary
This phase 3 study tests a personalized approach for HER2-positive breast cancer, using genetic and other data to adjust chemotherapy strength before surgery. The goal is to improve tumor shrinkage while reducing side effects. About 2,000 women with early-stage breast cancer will participate across multiple centers in China.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH HER2-POSITIVE BREAST CANCER (BC) SUITABLE FOR NEOADJUVANT THERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.